In the latest market close, Pfizer (PFE) reached $29.08, with a -0.27% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.77%. Meanwhile, the Dow ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie has been reporting an earnings decline because its former lead drug, Humira, lost patent-protected market exclusivity ...

However, 24 hours later, it's a good time for traders to examine the stocks and decide whether to buy the rally or take some ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

There was some intriguing news from a Pfizer (NYSE: PFE) shareholder on Thursday that was not taken well by the market.

On top of this, Pfizer also faces key patent expirations of certain older products, and earlier estimated this will result in ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...

Verizon's strength stems from its dominant U.S. wireless market position, controlling approximately 40% of the postpaid phone ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday. Shares of Pfizer Inc PFE rose during ...